LUCD vs. NNOX, CVRX, SNWV, TCMD, ZIMV, SMTI, LUNG, RCEL, NVRO, and ELMD
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Nano-X Imaging (NNOX), CVRx (CVRX), SANUWAVE Health (SNWV), Tactile Systems Technology (TCMD), ZimVie (ZIMV), Sanara MedTech (SMTI), Pulmonx (LUNG), AVITA Medical (RCEL), Nevro (NVRO), and Electromed (ELMD). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs.
Nano-X Imaging (NASDAQ:NNOX) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
Nano-X Imaging currently has a consensus target price of $17.50, suggesting a potential upside of 220.51%. Lucid Diagnostics has a consensus target price of $3.40, suggesting a potential upside of 113.84%. Given Nano-X Imaging's higher possible upside, equities analysts clearly believe Nano-X Imaging is more favorable than Lucid Diagnostics.
Nano-X Imaging has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
In the previous week, Lucid Diagnostics had 16 more articles in the media than Nano-X Imaging. MarketBeat recorded 19 mentions for Lucid Diagnostics and 3 mentions for Nano-X Imaging. Nano-X Imaging's average media sentiment score of 0.63 beat Lucid Diagnostics' score of 0.31 indicating that Nano-X Imaging is being referred to more favorably in the media.
Lucid Diagnostics received 7 more outperform votes than Nano-X Imaging when rated by MarketBeat users. However, 72.09% of users gave Nano-X Imaging an outperform vote while only 67.86% of users gave Lucid Diagnostics an outperform vote.
21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Lucid Diagnostics has lower revenue, but higher earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Nano-X Imaging has a net margin of -465.38% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Nano-X Imaging's return on equity.
Summary
Lucid Diagnostics beats Nano-X Imaging on 10 of the 19 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy LUCD Stock Free LUCD Stock Alerts